Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2018
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2018
SUMMARY
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 3 and 4 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Toxicology which include indications Insomnia, Narcolepsy, Sleep Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Obstructive Sleep Apnea, Opioid Induced Side Effects and Parkinson's Disease.
The latest report Orexin Receptor Type 2%li%Pipeline Review, H2 2018, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 3 and 4 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Toxicology which include indications Insomnia, Narcolepsy, Sleep Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Obstructive Sleep Apnea, Opioid Induced Side Effects and Parkinson's Disease.
The latest report Orexin Receptor Type 2%li%Pipeline Review, H2 2018, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
HTL-6641 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Eisai annonce presentation on lemborexant at (AAIC) 2018
Jul 02, 2018: Eisai to Give Oral Presentation on Results of Phase III Head-to-head Clinical Study of Lemborexant in Insomnia Disorder at 43rd Annual Meeting of the Japan Society of Sleep Research
Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
Jun 05, 2018: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting
Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Dec 21, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting
Dec 06, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
Oct 31, 2017: Eisai to Present Latest Data on lemborexant at 10th Clinical Trials on Alzheimer's Disease
Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
HTL-6641 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Eisai annonce presentation on lemborexant at (AAIC) 2018
Jul 02, 2018: Eisai to Give Oral Presentation on Results of Phase III Head-to-head Clinical Study of Lemborexant in Insomnia Disorder at 43rd Annual Meeting of the Japan Society of Sleep Research
Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
Jun 05, 2018: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting
Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Dec 21, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting
Dec 06, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
Oct 31, 2017: Eisai to Present Latest Data on lemborexant at 10th Clinical Trials on Alzheimer's Disease
Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Evotec AG, H2 2018
Pipeline by Heptares Therapeutics Ltd, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by OptiNose US Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Evotec AG, H2 2018
Pipeline by Heptares Therapeutics Ltd, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by OptiNose US Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Actelion Pharmaceuticals Ltd
Eisai Co Ltd
Evotec AG
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
